Neoadjuvant chemotherapy (NAC) has been shown to improve the outcome in patients with locally advanced inoperable or operable breast cancer. An early imaging assessment of response to NAC is critical for managing breast cancer to minimize the toxic side effects of ineffective chemotherapy. In this study, we have used an integrated diffusion-weighted imaging approach for simultaneous assessment of tissue cellularity, vascularity, and heterogeneity – DISMANTLE – from a full b-value spectrum to predict breast cancer’s response to NAC. Histogram features of pre-treatment DISMANTLE parameters were evaluated for predicting tumor response to NAC in terms of pathological complete response.
This abstract and the presentation materials are available to members only; a login is required.